Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (March 16th Preview)
-
Structure’s oral GLP-1 pill posts strong midstage results — dosing tweak steadies tolerability
Structure Therapeutics reported Phase 2 efficacy and tolerability data for its oral GLP-1 candidate aleniglipron showing pronounced weight loss and improved retention. In a trial of 61 treated patients, step-up dosing to 120 mg and higher produced up to ~15% body-weight reduction at 44 weeks; the company later highlighted a 16% placebo-adjusted result in broader reporting. Structure attributed fewer discontinuations to a slower dose escalation strategy. Analysts quoted in company coverage called the results competitive with upcoming oral entrants from Eli Lilly and Novo Nordisk and said the pill could pressure market dynamics for oral versus injectable GLP-1s. The data now set the stage for a Phase 3 push amid intensifying regulatory and commercial competition for oral obesity therapies.
-
Illumina and Veritas launch preventive genomics consortium — WGS moves upstream
Illumina and Veritas Genetics announced a consortium to integrate whole-genome sequencing into preventive healthcare pathways across the U.S. and other markets. Illumina will bring sequencing, DRAGEN pipelines and AI-enabled analytics; Veritas contributes patient-ready myGenome reporting, clinical interpretation and genetic counseling access. The program offers opt-in preventive genomics with confirmatory testing, specialist referral and guideline-aligned screening, and aims to build a consented clinical-genomics dataset for downstream industry partnerships. Illumina framed the alliance as a step toward embedding genomics earlier in care delivery.
-
CirCode wins FDA clearance to begin first-in-human circular RNA trial in US
CirCode Biomed received U.S. FDA clearance to start a clinical trial testing a circular RNA therapeutic, the company told Endpoints News. The IND greenlight permits CirCode to evaluate safety and early activity of its circular RNA platform in human subjects in the United States, marking a notable regulatory step for an emergent genetic-medicine modality. CirCode will now recruit for the protocol and initiate dosing under FDA supervision, positioning the startup among the first to take circular RNA constructs into human testing.
-
Unixell’s iPSC-derived cell therapy gets FDA IND for focal epilepsy
Shanghai Unixell Biotechnology secured FDA IND clearance to test UX-GIP001, an allogeneic iPSC-derived cell therapy for focal epilepsy, the company reported. The Phase I study will evaluate safety and feasibility in patients with drug-resistant focal epilepsy, marking a rare U.S. IND for an iPSC-derived neurological cell product. Unixell plans to initiate clinical operations under the IND, which opens the pathway to human dose escalation and translational data for cell-based approaches to refractory epilepsy.
-
Akeso secures NMPA go-ahead for trispecific cancer antibody AK-150
Akeso Inc. obtained IND clearance from China’s National Medical Products Administration for AK-150, a first-in-class trispecific antibody targeting advanced solid tumors. The approval authorizes Akeso to begin clinical evaluation in China, enabling dose-finding and early safety studies for the trispecific candidate. Akeso will proceed to patient enrollment under NMPA oversight, advancing its pipeline of next-generation antibody therapeutics aimed at solid tumor indications.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.